Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design

Bibliography

• Smith MZ, Wightman F, Lewin SR. HIV reservoirs and strategies for eradication. Curr HIV AIDS Rep 2012;9:5-15
   PubMedGoogle Scholar
• Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012;26:1261-8
   PubMed Web of Science ®Google Scholar
• Deeks SG, Autran B, Berkhout B, Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012;12:607-14
   PubMed Web of Science ®Google Scholar
• Palmer S, Josefsson L, Coffin JM. HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 2011;270:550-60
   PubMed Web of Science ®Google Scholar
• Barbaro G, Scozzafava A, Mastrolorenzo A, Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-43
   PubMed Web of Science ®Google Scholar
• Rusconi S, Scozzafava A, Mastrolorenzo A, An update in the development of HIV entry inhibitors. Curr Top Med Chem 2007;7:1273-89
   PubMed Web of Science ®Google Scholar
• Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends–is a paradigm change coming soon? Methods Mol Biol 2009;525:1-27, xiii
   PubMedGoogle Scholar
• Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012;899:1-26
   PubMedGoogle Scholar
• Chen W, Dimitrov DS. Monoclonal antibody-based candidate therapeutics against HIV type 1. AIDS Res Hum Retroviruses 2012;28:425-34
   PubMed Web of Science ®Google Scholar
• Gong R, Chen W, Dimitrov DS. Candidate antibody-based therapeutics against HIV-1. BioDrugs 2012;26:143-62
   PubMed Web of Science ®Google Scholar
• Ada GL. Human vaccines. Dev Biol Stand 1994;82:181-8
   PubMedGoogle Scholar
• Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs 1998;10:137-58
   PubMed Web of Science ®Google Scholar
• Li G, Chen W, Yan W, Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes. Virology 2004;328:274-81
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Alam SM, Liao HX, HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 2012;20:532-9
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20
   PubMed Web of Science ®Google Scholar
• Hutter G, Nowak D, Mossner M, Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-8
   PubMed Web of Science ®Google Scholar
• Chen W, Dimitrov DS. Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 2009;4:112-17
   PubMedGoogle Scholar
• Burton DR, Poignard P, Stanfield RL, Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183-6
   PubMed Web of Science ®Google Scholar
• Roben P, Moore JP, Thali M, Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-8
   PubMed Web of Science ®Google Scholar
• Buchacher A, Predl R, Strutzenberger K, Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-69
   PubMed Web of Science ®Google Scholar
• Purtscher M, Trkola A, Gruber G, A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994;10:1651-8
   PubMed Web of Science ®Google Scholar
• Stiegler G, Kunert R, Purtscher M, A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001;17:1757-65
   PubMed Web of Science ®Google Scholar
• Walker LM, Phogat SK, Chan-Hui PY, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-9
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li Y, Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329:856-61
   PubMed Web of Science ®Google Scholar
• Scheid JF, Mouquet H, Ueberheide B, Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011;333:1633-7
   PubMed Web of Science ®Google Scholar
• Diskin R, Scheid JF, Marcovecchio PM, Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011;334:1289-93
   PubMed Web of Science ®Google Scholar
• Wu X, Zhou T, Zhu J, Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011;333:1593-602
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-70
   PubMed Web of Science ®Google Scholar
• Huang J, Ofek G, Laub L, Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012;491:406-12
   PubMed Web of Science ®Google Scholar
• Zhu Z, Qin HR, Chen W, Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol 2011;85:11401-8
   PubMed Web of Science ®Google Scholar
• Abela IA, Berlinger L, Schanz M, Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 2012;8:e1002634
   PubMed Web of Science ®Google Scholar
• Dimitrov DS, Willey RL, Sato H, Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993;67:2182-90
   PubMed Web of Science ®Google Scholar
• Chen W, Zhu Z, Feng Y, Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008;105:17121-6
   PubMed Web of Science ®Google Scholar
• Forsman A, Beirnaert E, Aasa-Chapman MM, Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008;82:12069-81
   PubMed Web of Science ®Google Scholar
• McCoy LE, Quigley AF, Strokappe NM, Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med 2012;209:1091-103
   PubMed Web of Science ®Google Scholar
• Sun M, Pace C, Yu J, Rational design of a novel bispecific HIV-1-neutralizing antibody, Ibalizumabm36 [abstracts:436]. 18th Conference on Retroviruses and Opportunistic Infections; 2012
   Google Scholar
• Pegu A, Yang Z, Chen X, VRC01 provides sterilizing protection to non human primates from mucosal SHIV challenges. J Immunol 2011;186:155.11
   Google Scholar
• Zhang C, Zheng J, Chen W, Protective immunity: eAd inhibit in vivo HIV infection in humanized mice and can be expressed by lentiviral vectors to reprogam cells to secrete broadly neutralizing anti-HIV antibodies [abstracts:379]. 18th Conference on Retroviruses and Opportunistic Infections; 2011
   Google Scholar
• Klein F, Halper-Stromberg A, Horwitz JA, HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012
   Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012;481:81-4
   PubMed Web of Science ®Google Scholar
• Gray ES, Madiga MC, Moore PL, Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009;83:11265-74
   PubMed Web of Science ®Google Scholar
• Shen X, Parks RJ, Montefiori DC, In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009;83:3617-25
   PubMed Web of Science ®Google Scholar
• Zhang MY, Wang Y, Mankowski MK, Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 2009;27:857-63
   PubMed Web of Science ®Google Scholar
• Joyce JG, Hurni WM, Bogusky MJ, Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 2002;277:45811-20
   PubMed Web of Science ®Google Scholar
• Zhou M, Kostoula I, Brill B, Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. Vaccine 2012;30:1911-16
   Google Scholar
• Dennison SM, Sutherland LL, Jaeger FH, Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One 2011;6:e27824
   PubMed Web of Science ®Google Scholar
• Cardoso RM, Zwick MB, Stanfield RL, Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005;22:163-73
   PubMed Web of Science ®Google Scholar
• Ofek G, Tang M, Sambor A, Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004;78:10724-37
   PubMed Web of Science ®Google Scholar
• Ofek G, Guenaga FJ, Schief WR, Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci USA 2010;107:17880-7
   PubMed Web of Science ®Google Scholar
• Correia BE, Ban YE, Holmes MA, Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 2010;18:1116-26
   PubMed Web of Science ®Google Scholar
• Guenaga J, Dosenovic P, Ofek G, Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 2011;6:e16074
   PubMedGoogle Scholar
• Burton DR. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci USA 2010;107:17859-60
   PubMed Web of Science ®Google Scholar
• Haynes BF, Fleming J, St Clair EW, Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005;308:1906-8
   PubMed Web of Science ®Google Scholar
• Sanchez-Martinez S, Lorizate M, Katinger H, Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 2006;22:998-1006
   PubMed Web of Science ®Google Scholar
• Xiao XD, Chen WZ, Feng Y, Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses Basel 2009;1:802-17
   PubMed Web of Science ®Google Scholar
• Alam SM, Morelli M, Dennison SM, Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009;106:20234-9
   PubMed Web of Science ®Google Scholar
• Ofek G, McKee K, Yang Y, Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010;84:2955-62
   PubMed Web of Science ®Google Scholar
• Kim M, Sun ZY, Rand KD, Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 2011;18:1235-43
   PubMed Web of Science ®Google Scholar
• Matyas GR, Wieczorek L, Beck Z, Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009;23:2069-77
   PubMed Web of Science ®Google Scholar
• Xiang SH, Kwong PD, Gupta R, Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 2002;76:9888-99
   PubMed Web of Science ®Google Scholar
• Martin G, Burke B, Thai R, Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. J Biol Chem 2011;286:21706-16
   PubMed Web of Science ®Google Scholar
• Fouts TR, Tuskan R, Godfrey K, Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 2000;74:11427-36
   PubMed Web of Science ®Google Scholar
• DeVico A, Fouts T, Lewis GK, Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA 2007;104:17477-82
   PubMed Web of Science ®Google Scholar
• Decker JM, Bibollet-Ruche F, Wei X, Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005;201:1407-19
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Poignard P, Raja A, Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003;77:10557-65
   PubMed Web of Science ®Google Scholar
• Zhou T, Xu L, Dey B, Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007;445:732-7
   PubMed Web of Science ®Google Scholar
• Dey B, Svehla K, Xu L, Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 2009;5:e1000445
   PubMed Web of Science ®Google Scholar
• Dey B, Pancera M, Svehla K, Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol 2007;81:5579-93
   PubMed Web of Science ®Google Scholar
• Feng Y, McKee K, Tran K, Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem 2012;287:5673-86
   PubMed Web of Science ®Google Scholar
• Chen W, Feng Y, Wang Y, Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies. Biochem Biophys Res Commun 2012;425:931-7
   PubMed Web of Science ®Google Scholar
• Tran EE, Borgnia MJ, Kuybeda O, Structural mechanism of Trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 2012;8:e1002797
   PubMed Web of Science ®Google Scholar
• Meyerson JR, Tran EEH, Kuybeda O, Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc Natl Acad Sci USA In press
   Google Scholar
• Chen W, Zhu Z, Liao H, Cross-reactive human IgM-derived monoclonal antibodies that bind to HIV-1 envelope glycoproteins. Viruses 2010;2:547-65
   Google Scholar
• Phogat S, Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des 2007;13:213-27
   PubMed Web of Science ®Google Scholar
• Nkolola JP, Peng H, Settembre EC, Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 2010;84:3270-9
   PubMed Web of Science ®Google Scholar
• Kovacs JM, Nkolola JP, Peng H, HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA 2012;109:12111-16
   PubMed Web of Science ®Google Scholar
• Yang L, Song Y, Li X, HIV-1 Virus-Like Particles Produced by Stably Transfected Drosophila S2 Cells: a Desirable Vaccine Component. J Virol 2012;86:7662-76
   PubMed Web of Science ®Google Scholar
• Tong T, Crooks ET, Osawa K, HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol 2012;86:3574-87
   PubMed Web of Science ®Google Scholar
• Xiao X, Chen W, Feng Y, Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009;390:404-9
   PubMed Web of Science ®Google Scholar
• Ota T, Doyle-Cooper C, Cooper AB, Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. J Immunol 2012;189:4816-24
   PubMed Web of Science ®Google Scholar
• Hoot SJ, McGuire A, Cohen KW, Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog In press
   Web of Science ®Google Scholar
• Chen W, Streaker ED, Russ DE, Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem Biophys Res Commun 2012;417:1164-9
   PubMed Web of Science ®Google Scholar
• Xiao X, Feng Y, Chen W, Guiding the immune system through complex maturation pathways: a novel multi-immunogen approach for elicitation of broadly neutralizing antibodies. Retrovirology 2009;6:P35
   PubMedGoogle Scholar
• Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010;2:347-56
   PubMed Web of Science ®Google Scholar
• Haynes BF, Kelsoe G, Harrison SC, B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-33
   PubMed Web of Science ®Google Scholar
• Ma BJ, Alam SM, Go EP, Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 2011;7:e1002200
   Google Scholar
• Abbas W, Herbein G. Molecular understanding of HIV-1 Latency. Adv Virol 2012;2012:574967
   PubMedGoogle Scholar
• Chun TW, Carruth L, Finzi D, Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-8
   PubMed Web of Science ®Google Scholar
• Finzi D, Blankson J, Siliciano JD, Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-17
   PubMed Web of Science ®Google Scholar
• Zagury D, Bernard J, Leonard R, Long-term cultures of HTLV-III–infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986;231:850-3
   PubMed Web of Science ®Google Scholar
• Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987;326:711-13
   PubMed Web of Science ®Google Scholar
• Chun TW, Engel D, Mizell SB, Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-5
   PubMed Web of Science ®Google Scholar
• Scripture-Adams DD, Brooks DG, Korin YD, Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002;76:13077-82
   PubMed Web of Science ®Google Scholar
• Scheller C, Ullrich A, McPherson K, CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 2004;279:21897-902
   PubMed Web of Science ®Google Scholar
• Hezareh M. Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug News Perspect 2005;18:496-500
   PubMed Web of Science ®Google Scholar
• Dechristopher BA, Loy BA, Marsden MD, Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 2012;4:705-10
   PubMed Web of Science ®Google Scholar
• Ylisastigui L, Archin NM, Lehrman G, Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004;18:1101-8
   PubMed Web of Science ®Google Scholar
• Lehrman G, Hogue IB, Palmer S, Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005;366:549-55
   PubMed Web of Science ®Google Scholar
• Archin NM, Liberty AL, Kashuba AD, Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-5
   PubMed Web of Science ®Google Scholar
• Yang HC, Shen L, Siliciano RF, Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc Natl Acad Sci USA 2009;106:6321-6
   PubMed Web of Science ®Google Scholar
• Micheva-Viteva S, Kobayashi Y, Edelstein LC, High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem 2011;286:21083-91
   PubMed Web of Science ®Google Scholar
• Huang J, Wang F, Argyris E, Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007;13:1241-7
   PubMed Web of Science ®Google Scholar
• Moldt B, Shibata-Koyama M, Rakasz EG, A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012;86:6189-96
   PubMed Web of Science ®Google Scholar
• Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012;14:405-15
   PubMed Web of Science ®Google Scholar
• Kennedy PE, Bera TK, Wang QC, Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. J Leukoc Biol 2006;80:1175-82
   PubMed Web of Science ®Google Scholar
• Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 2010;6:e1000803
   PubMed Web of Science ®Google Scholar
• Davey RT Jr, Boenning CM, Herpin BR, Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994;170:1180-8
   PubMed Web of Science ®Google Scholar
• Wu X, Wang C, O'Dell S, Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol 2012;86:5844-56
   PubMed Web of Science ®Google Scholar
• Steckbeck JD, Sun C, Sturgeon TJ, Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes. PLoS ONE 2010;5:e15261
   PubMedGoogle Scholar
• Chun TW, Nickle DC, Justement JS, Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008;197:714-20
   PubMed Web of Science ®Google Scholar
• Chen W, Feng Y, Gong R, Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol 2011;85:9395-405
   PubMed Web of Science ®Google Scholar
• Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 2012;26:447-81. vii
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol 2008;4:457-69
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Buccisano F, Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008;34:49-60
   PubMed Web of Science ®Google Scholar